{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:38:51Z","timestamp":1787960331896,"version":"build-2784847793"},"reference-count":15,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2014,4,13]],"date-time":"2014-04-13T00:00:00Z","timestamp":1397347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the efficacy and safety of tamsulosin dose increase to 0.4\u2009mg daily in <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>sian patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia refractory to tamsulosin 0.2\u2009mg treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We carried out a 12\u2010week, single\u2010center, randomized, placebo\u2010controlled trial in 220 patients. Patients treated with 0.2\u2009mg tamsulosin daily without other lower urinary tract symptoms secondary to benign prostatic hyperplasia medication for more than 3\u2009months and refractory to this treatment were enrolled. We defined \u201crefractory\u201d as an International Prostate Symptom Score of 13 or greater and a maximum flow rate of 15 or under despite medication. Patients with a surgical history related to lower urinary tract symptoms secondary to benign prostatic hyperplasia or a postvoid residual of 150\u2009mL or greater were excluded. Eligible patients were randomly assigned to the 0.4\u2009mg group (two tablets of 0.2\u2009mg tamsulosin once daily) or the 0.2\u2009mg group (one tablet of 0.2\u2009mg tamsulosin and one tablet of placebo once daily). International Prostate Symptom Score, maximum flow rate, blood pressure, heart rate, and adverse events were compared between the two groups at 4\u2009weeks and 12\u2009weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 220 patients were enrolled and analyzed. There were no differences in baseline characteristics between the two groups. After 12\u2009weeks of medication, the International Prostate Symptom Score was not different between the two groups. However, the improvement in maximum flow rate was greater in the 0.4\u2009mg group than the 0.2\u2009mg group (3.0\u2009\u00b1\u20090.48\u2009mL\/s <jats:italic>vs<\/jats:italic> \u22120.25\u2009\u00b1\u20090.30\u2009mL\/s, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). The proportion of patients who showed an increase in maximum flow rate of more than 5\u2009mL\/s was 10.9% in the 0.2\u2009mg group versus 16.3% in the 0.4\u2009mg group (<jats:italic>P<\/jats:italic>\u2009=\u20090.209). There were no significant differences in bother score or postvoid residual between the two groups. Systolic and diastolic blood pressure, and heart rate were also not different between the two groups. The incidence of adverse events was 10.9% in the 0.2\u2009mg group (dizziness 5.5%; abnormal ejaculation 1.8%; palpitation 1.8%; and headache 1.8%) and 9.09% in the 0.4\u2009mg group (dizziness 3.6%; abnormal ejaculation 1.8%; palpitations 1.8%; and headache 1.8%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Tamsulosin 0.4\u2009mg appears to be a safe treatment regimen for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia in <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>sian patients who do not respond to 0.2\u2009mg treatment. Increasing the dose of tamsulosin results in a significant improvement in maximum flow rate without any increase in cardiovascular complications.<\/jats:p><\/jats:sec>","DOI":"10.1111\/iju.12412","type":"journal-article","created":{"date-parts":[[2014,4,14]],"date-time":"2014-04-14T00:14:40Z","timestamp":1397434480000},"page":"677-682","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and tolerability of tamsulosin 0.4\u2009mg in <scp>A<\/scp>sian patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia refractory to tamsulosin 0.2\u2009mg: A randomized placebo controlled trial"],"prefix":"10.1111","volume":"21","author":[{"given":"Jung Jun","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Urology Samsung Medical Center Sungkyunkwan University School of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok Hyun","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Urology Samsung Medical Center Sungkyunkwan University School of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Hwan","family":"Sung","sequence":"additional","affiliation":[{"name":"Department of Urology Samsung Medical Center Sungkyunkwan University School of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seol Ho","family":"Choo","sequence":"additional","affiliation":[{"name":"Department of Urology Samsung Medical Center Sungkyunkwan University School of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Urology Samsung Medical Center Sungkyunkwan University School of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,13]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200219020-00004"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262010-00006"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)39620-9"},{"key":"e_1_2_8_5_1","first-page":"231","article-title":"Urodynamic findings in patients with lower urinary tract symptoms and small prostate volumes","volume":"29","author":"Choi JB","year":"2011","journal-title":"World J. Mens Health"},{"key":"e_1_2_8_6_1","first-page":"231","article-title":"Clinical evaluation of YM617 on bladder outlet obstruction associated with benign prostatic hypertrophy\u2013a double\u2010blind, multicentre study compared with placebo","volume":"4","author":"Kawabe K","year":"1991","journal-title":"Jpn. J. Urol. Surg."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00126-5"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1995.tb07709.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S0022-5347(01)62386-3","article-title":"A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93\u201001 Study Group","volume":"160","author":"Narayan P","year":"1998","journal-title":"J. Urol."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2003.03077.x"},{"key":"e_1_2_8_11_1","volume-title":"Benign Prostatic Hyperplasia","author":"Chatelain C","year":"2001"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6777(1998)17:2<99::AID-NAU3>3.0.CO;2-7"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365590902811537"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10624.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.02.055"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.11.026"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fiju.12412","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.12412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T07:34:54Z","timestamp":1696232094000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.12412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,13]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1111\/iju.12412"],"URL":"https:\/\/doi.org\/10.1111\/iju.12412","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,13]]}}}